Coherus BioSciences, Inc. - CHRS STOCK NEWS

Junshi Biosciences and Coherus BioSciences announced positive results from the pivotal CHOICE-01 Phase 3 clinical trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC) patients without EGFR/ALK mutations. The trial met its primary endpoint of progression-free survival (PFS) and a secondary endpoint of overall survival (OS), showing a median PFS of 8.4 months versus 5.6 months with chemotherapy alone (HR=0.49). The study revealed a manageable safety profile and the potential for future trials based on biomarker data. The FDA has granted priority review for toripalimab.

Coherus BioSciences (Nasdaq: CHRS) announced its participation in two key investor conferences in March 2022. The 42nd Annual Cowen Health Care Conference will take place on March 9 at 10:30 a.m. ET, followed by the Barclays Global Healthcare Conference on March 15 at 2:35 p.m. ET. Audio webcasts of both presentations will be available on the investors' section of Coherus' website and will remain archived for 30 days. Investors are encouraged to access the site beforehand for a timely connection.

Coherus BioSciences (CHRS) and Junshi Biosciences announced the publication of results from the JUPITER-06 trial demonstrating that toripalimab combined with chemotherapy significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced esophageal squamous cell carcinoma (ESCC). The trial, which involved 514 treatment-naïve patients, showed median OS at 17 months (toripalimab) versus 11 months (placebo), with a hazard ratio of 0.58. Notably, benefits were observed across all PD-L1 expression subgroups, including those with low expression.

Coherus BioSciences (NASDAQ: CHRS) reported Q4 and FY 2021 results, highlighting a net revenue of $73 million in Q4 and $327 million for the year, reflecting declines attributed to increased competition and COVID-19 impacts. The FDA approved YUSIMRY, with a projected launch in 2023, and toripalimab's BLA received priority review for nasopharyngeal carcinoma. The company aims for further diversification with the anticipated launch of CIMERLI. Financial guidance for 2022 estimates combined R&D and SG&A expenses between $415 million and $450 million, coupled with significant projected losses.

Coherus BioSciences has appointed Paul Reider as Chief Commercial Officer, enhancing its leadership as it prepares to launch up to five new products in the next 18 months. Reider brings 30 years of biopharmaceutical experience, including significant roles in marketing and sales at Amgen, Puma Biotechnology, and Ipsen. His expertise includes launching specialty brands and managing blockbuster oncology drugs. Coherus aims to expand its immuno-oncology franchise, backed by the upcoming FDA review of toripalimab, with a target action date of April 2022.

Coherus BioSciences announced on February 14, 2022, the granting of stock options for 236,500 shares to new employees at an exercise price of $12.44. This includes a significant grant of 45,000 shares to a Vice President and 191,500 shares to other non-officer employees. This move aims to incentivize talent under the 2016 Employment Commencement Incentive Plan. Coherus is advancing its immuno-oncology portfolio and has a biologics license application for toripalimab under FDA review, targeting an April 2022 decision date.

Coherus BioSciences (Nasdaq: CHRS) will release its Q4 and full-year 2021 financial results on February 17, 2022, after market close. A conference call and webcast will follow at 5 p.m. ET to discuss these results and provide a business update. Investors can access the results on Coherus' website following the announcement. Interested parties are advised to dial in 15 minutes early for the call. The contact for investor relations is Cheston Turbyfill, reachable at IR@coherus.com.

Coherus BioSciences (Nasdaq: CHRS) announces the appointment of Lee N. Newcomer, M.D. to its Board of Directors, effective February 2, 2022, following the resignation of Jim Healy. With extensive experience in oncology and healthcare, Dr. Newcomer's expertise is expected to enhance Coherus' strategic direction, particularly for the upcoming launch of YUSIMRY™ in the U.S. adalimumab market and its immuno-oncology efforts, including toripalimab. The company aims to build a leading franchise with innovative therapies while continuing to generate revenue from its biosimilars.

Coherus BioSciences (CHRS) and Junshi Biosciences have expanded their immuno-oncology collaboration to evaluate the combination of toripalimab and JS006, a novel TIGIT-targeted antibody, in clinical trials across various tumor types. Coherus will pay Junshi $35 million upfront, up to $255 million in milestones, and an 18% royalty on net revenue. This partnership aims to enhance checkpoint inhibitor efficacy in patients with advanced solid tumors. The FDA has granted priority review for toripalimab's biologics license application, advancing the potential treatment landscape for cancers like nasopharyngeal carcinoma.